<code id='15DC1EE41F'></code><style id='15DC1EE41F'></style>
    • <acronym id='15DC1EE41F'></acronym>
      <center id='15DC1EE41F'><center id='15DC1EE41F'><tfoot id='15DC1EE41F'></tfoot></center><abbr id='15DC1EE41F'><dir id='15DC1EE41F'><tfoot id='15DC1EE41F'></tfoot><noframes id='15DC1EE41F'>

    • <optgroup id='15DC1EE41F'><strike id='15DC1EE41F'><sup id='15DC1EE41F'></sup></strike><code id='15DC1EE41F'></code></optgroup>
        1. <b id='15DC1EE41F'><label id='15DC1EE41F'><select id='15DC1EE41F'><dt id='15DC1EE41F'><span id='15DC1EE41F'></span></dt></select></label></b><u id='15DC1EE41F'></u>
          <i id='15DC1EE41F'><strike id='15DC1EE41F'><tt id='15DC1EE41F'><pre id='15DC1EE41F'></pre></tt></strike></i>

          Home / Wikipedia / Wikipedia

          Wikipedia


          Wikipedia

          author:hotspot    Page View:698
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe

          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 

          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?

          advertisement

          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In